Oscar Health (NYSE:OSCR - Get Free Report)'s stock had its "sell (d)" rating restated by equities researchers at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.
OSCR has been the subject of a number of other research reports. Barclays dropped their price objective on Oscar Health from $17.00 to $11.00 and set an "underweight" rating for the company in a report on Wednesday, July 23rd. Piper Sandler lowered their price target on Oscar Health from $14.00 to $13.00 and set a "neutral" rating for the company in a report on Thursday, August 14th. UBS Group restated a "sell" rating and issued a $11.00 price target (down from $15.00) on shares of Oscar Health in a report on Tuesday, July 15th. Robert W. Baird restated a "neutral" rating and issued a $14.00 price target (down from $28.00) on shares of Oscar Health in a report on Friday, July 25th. Finally, Wall Street Zen downgraded Oscar Health from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Four investment analysts have rated the stock with a Hold rating and six have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Strong Sell" and a consensus price target of $12.64.
Check Out Our Latest Stock Report on Oscar Health
Oscar Health Trading Up 1.1%
NYSE OSCR opened at $22.04 on Wednesday. The stock has a 50-day simple moving average of $17.54 and a 200 day simple moving average of $15.77. The company has a market capitalization of $5.70 billion, a PE ratio of -27.18 and a beta of 1.89. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 0.26. Oscar Health has a 12 month low of $11.20 and a 12 month high of $23.80.
Oscar Health (NYSE:OSCR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.89) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.01. The business had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.88 billion. Oscar Health had a negative return on equity of 13.78% and a negative net margin of 1.50%.The firm's revenue was up 29.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 earnings per share. Research analysts forecast that Oscar Health will post 0.69 EPS for the current year.
Insider Buying and Selling
In other Oscar Health news, insider Mario Schlosser sold 395,000 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $18.43, for a total transaction of $7,279,850.00. Following the sale, the insider owned 501,148 shares in the company, valued at $9,236,157.64. This represents a 44.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 24.39% of the company's stock.
Institutional Investors Weigh In On Oscar Health
Several institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. increased its stake in Oscar Health by 23.8% in the first quarter. Victory Capital Management Inc. now owns 285,997 shares of the company's stock valued at $3,749,000 after acquiring an additional 54,938 shares during the last quarter. Concurrent Investment Advisors LLC bought a new position in Oscar Health in the first quarter valued at $677,000. Nuveen LLC bought a new position in Oscar Health in the first quarter valued at $29,684,000. NewEdge Advisors LLC increased its stake in Oscar Health by 89.7% in the first quarter. NewEdge Advisors LLC now owns 188,058 shares of the company's stock valued at $2,465,000 after acquiring an additional 88,946 shares during the last quarter. Finally, Matauro LLC bought a new position in Oscar Health in the second quarter valued at $1,508,000. Hedge funds and other institutional investors own 75.70% of the company's stock.
Oscar Health Company Profile
(
Get Free Report)
Oscar Health, Inc operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oscar Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oscar Health wasn't on the list.
While Oscar Health currently has a Strong Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.